Acumen Pharmaceuticals (ABOS)
(Delayed Data from NSDQ)
$1.35 USD
-0.05 (-3.57%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.35 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Acumen Pharmaceuticals, Inc.'s return on equity, or ROE, is -58.24% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that ABOS has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ABOS 1.35 -0.05(-3.57%)
Will ABOS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ABOS based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ABOS
ABOS: Acumen Pharmaceuticals Cuts Clinical Trial Costs with Innovative Assay
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for ...
Acumen presents results from its Phase 2 ALTITUDE-AD study of sabirnetug
Tesla, Alphabet Set To Report Earnings As Investors Watch Out For Jobless Claims And Durable Goods Orders
Catalyst Watch: Alphabet earnings, McGraw Hill IPO, Trump talks AI, and more robotaxi buzz